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Abstract 
In this study, human globular adiponectin-glucagon-like peptide-1 analog (gAd-GLP-1-A) fu-
sion protein was expressed and its glucose-lowering effect was measured in vivo. We con-
structed a prokaryotic expression vector PET28a-gAd-GLP-1-A and transformed the vector 
into Escherichia coli BL21 (DE3). A recombinant fusion protein of about 25KD was expressed 
from  BL21  (DE3)  cells  after  isopropylthio--D-galactoside  induction.  This  protein  was 
N-terminal His-tagged gAd-GLP-1-A fusion protein. Most of the protein was expressed in 
inclusion body. The fusion protein in inclusion body was purified by using High-Affinity 
Nickel Iminodiacetic Acid Resin and refolded in urea gradient refolding buffer. The refolded 
protein was incubated with enterokinase to remove the N-terminal His-tag. The fusion 
protein  without  His-tag  is  gAd-GLP-1-A  fusion  protein,  which  exhibited  significant  glu-
cose-lowering effect in diabetic mice. 
Key words: Escherichia coli, Expression, Globular adiponectin, Globular adiponectin-glucagon-like 
peptide-1 analog fusion protein, Glucagon-like peptide-1 analog 
Introduction 
Adiponectin  is  an  adipocyte-specific  secretory 
protein that circulates in blood at high concentrations 
[1]. It plays important roles in regulating insulin sen-
sitivity and blood glucose levels. Current data have 
suggested that adiponectin is implicated in the path-
ogenesis  of  type  2  diabetes  [1].  Blood  adiponectin 
levels are markedly reduced in patients with type 2 
diabetes  [1].  Administration  of  recombinant  adi-
ponectin can improve insulin sensitivity and signifi-
cantly reduce blood glucose in diabetic mice [1]. Fur-
thermore,  adiponectin  has  been  reported  to  exhibit 
protective  effects  against  atherosclerosis  and  have 
roles  in  regulating  lipid  metabolism  [1].  Based  on 
these beneficial effects, adiponectin has been gener-
ally studied as a  promising candidate for the treat-
ment of type 2 diabetes [1]. Adiponectin is a protein of 
247 amino acids consisting of four domains, an ami-
no-terminal signal sequence (1-18 amino acid), a var-
iable region (19-41 amino acid), a collagenous domain 
(42-107  amino  acid),  and  a  C-terminal  globular  do-
main (globular adiponectin, 108-244 amino acid) [2]. 
In  these  four  domains,  globular  adiponectin  (gAd), 
which  has  been  confirmed  to  have  greater  potency 
than full-length adiponectin, has the potential to be-Int. J. Med. Sci. 2011, 8 
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come a novel therapeutic agent for the treatment of 
type 2 diabetes [2]. 
Glucagon-like  peptide  1  (GLP-1)  is  an  incretin 
hormone  released  from  islet  -cell  and  intestinal 
L-cells in response to the ingestion of food [3]. It plays 
an  important  role  in  glucose  homeostasis  and  has 
shown promising effects as a new treatment for type 2 
diabetic patients [3]. The main function of GLP-1 is to 
enhance  glucose-dependent  insulin  secretion  [3]. 
Administration of GLP-1 can increase insulin secre-
tion  and  reduce  blood  glucose  [3].  GLP-1  also  pro-
motes  islet  β-cell  proliferation,  suppresses  glucagon 
secretion, reduces hepatic glucose production, inhibit 
appetite,  and  slow  the  rate  of  gastric  emptying  [3]. 
GLP-1 (1-37), the intracellular precursor of GLP-1, is 
cleaved  from  proglucagon,  and  the  first  six  amino 
acids are subsequently removed from the N terminus 
to form bioactive peptides [4]. The principal biologi-
cally active forms of GLP-1 are: GLP-1 (7-37) and the 
predominant  circulating  active  form  GLP-1  (7-36) 
amide [4]. In vivo, both peptides have equipotent bi-
ological effects [4]. However, the potential for using 
GLP-1 to lower blood glucose is limited by its very 
short plasma half-life [5, 6]. This is due to its rapid 
inactivation by dipeptidyl peptidase IV and by renal 
clearance.  Developing  long-acting  GLP-1  analogs 
(GLP-1-A)  to  circumvent  the  rapid  inactivation  and 
renal  clearance  of  GLP-1  is  therefore  an  important 
step toward applying them therapeutically [5, 6]. 
Type  2  diabetes  is  characterized  by  insulin  re-
sistance and insulin secretion deficiency. At present, 
there  is  no  a  single  medication  which  treats  type  2 
diabetes  by  improving  both  insulin  resistance  and 
insulin secretion deficiency. This study was designed 
to express human globular adiponectin-glucagon-like 
peptide-1 analog (gAd-GLP-1-A) fusion protein from 
Escherichia coli strain BL21 (DE3) and investigate its 
glucose-lowering effect in diabetic mouse model. The 
GLP-1-A, which should have greater plasma stability 
and  longer  biological  half-life,  was  generated  by  a 
substitution of glycolamine for alanine at the second 
site of GLP-1 (7-37) [7]. 
Materials and medhods 
Materials 
Male KM mice (weight 18-20g) were provided by 
Experimental  Animal  centre,  Zhejiang  Chinese 
Medical University (Hangzhou, China). Plasmid vec-
tor PET28a and Escherichia coli host strain BL21 (DE3) 
were obtained from Zhejiang University Institute of 
Life Sciences (Hangzhou, China). Mouse anti-His-tag 
monoclonal antibody was purchased from Novagen 
Company  (Germany).  Streptozocin  was  obtained 
from  Sigma  Company  (USA).  High-Affinity  Nickel 
Iminodiacetic Acid (Ni-IDA) Resin and enterokinase 
were the products  of GenScript Corporation (USA). 
BCA Protein Assay Kit was purchased from Beyotime 
Institute of Biotechnology (Jiangshu, China). 
Construction of recombinant vector 
PET28a-gAd-GLP-1-A 
Recombinant  vector  PET28a-gAd-GLP-1-A  was 
constructed according to previous method established 
by  our  laboratory  (Patent  No:  200510050844.8)  [8]. 
Briefly, GLP-1-A gene was obtained by designing a 
mutation in the gene of GLP-1 (7-37). This mutation 
resulted in the substitution of glycolamine for alanine 
at the second site of GLP-1 (7-37) peptide. A sequence 
of nucleotide including 45 bases was used to connect 
the 3’ terminus of GLP-1-A gene and 5’ terminus of 
gAd  gene.  The  product  of  this  nucleotide  sequence 
was a glycine-rich short peptide including 15 amino 
acids: [N-(Serine-glycine)7- Serine-C], which was used 
as a linker to connect the N-terminus of gAd and the 
C-terminus of GLP-1-A. Because the protein produced 
from  plasmid  vector  PET28a  was  an  N-terminal 
6×His-tagged protein, we introduced an enterokinase 
cleavage  site  at  the  5’  terminus  of  the  gene  of 
gAd-GLP-1-A fusion protein, which was used to re-
move the N-terminus His-tag [9]. The gene encoding 
the gAd-GLP-1-A fusion protein was cloned into the 
expression vector PET28a at Nhe I and HindIII sites. 
Expression of N-terminal His-tagged 
gAd-GLP-1-A fusion protein and Western blot 
analysis 
Protein  expression:  The  Escherichia  coli  BL21 
(DE3) transformed with  PET28a-gAd-GLP-1-A were 
spread in Luria-Bertani liquid medium (1% tryptone, 
1%  NaCl,  0.5%  yeast  extract,  w/v,  pH  7.0)  supple-
mented with 80mg Kanamycin /l and cultured over-
night  at  37°C.  Typically,  2mL  of  overnight  grown 
culture  was  added  to  200mL  of  medium  and  incu-
bated with shaking at 37°C until optical density at 600 
nm  reached  0.4-0.6.  Isopropylthio--D-galactoside 
(IPTG)  was  then  added  to  a  ﬁnal  concentration  of 
0.4mM and bacterial were cultured for additional 4h 
at 37°C in shaking incubator to induce the His-tagged 
gAd-GLP-1-A  fusion  protein  expression.  Bacterial 
cells were harvested by centrifugation at 5000 rpm for 
10 min at 4°C, washed with 0.1M phosphate-buffered 
saline  (PBS,  pH  7.4) for  three  times.  The  sediments 
were resuspended with 0.1 M PBS, sonicated on ice 
for 30min, and then recentrifuged in order to separate 
the supernatant and inclusion body. Part of the pro-
duction was applied to a 12% SDS–PAGE. 
Western blot analysis: The supernatant and in-Int. J. Med. Sci. 2011, 8 
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clusion body were analyzed by 12% gels SDS–PAGE, 
and  then  transferred  to  a  nitrocellulose  membrane 
(1h,  100V).  Following  transfer,  the  membrane  was 
blocked in Tris Buffered Saline with Tween-20 con-
taining 50g/L skimmed milk for 2h, and then incu-
bated with mouse anti-His-tag monoclonal antibody 
for 2h at room temperature. The strips were washed 
three times with Tris Buffered Saline (5min each time) 
and  then  incubated  with  horseradish  peroxi-
dase-conjugated  second  antibody  for  2h,  washed 
again  with  Tris  Buffered  Saline  as  described  previ-
ously,  and  finally  developed  with 
5-Bromo-4-Chloro-3-Indolyl  Phosphate  /Nitro  blue 
tetrazolium solution. 
Purification and refolding of N-terminal 
His-tagged gAd-GLP-1-A fusion protein 
The  inclusion  body  were  washed  in  washing 
buffer I (0.5% Triton  X-100, 50mM Tris-HCl, 10mM 
EDTA, pH 8.0) for three times, and then in washing 
buffer II (2M urea, 50mM Tris-HCl, 10 mM EDTA, pH 
8.0)  for  two  times.  The  sediment  was  dissolved  in 
Binding Buffer (5mM imidazole, 0.5M sodium chlo-
ride, 20mM Tris, 8M urea, pH 7.9) at 4°C for about 2h. 
The insoluble materials were removed by centrifuga-
tion  at  12000g  at  4°C  for  15  min.  The  N-terminal 
His-tagged  gAd-GLP-1-A  fusion  protein  was  dis-
solved  in  the  supernatant.  The  fusion  protein  was 
purified by High-Affinity Ni-IDA Resin. The column 
was  equilibrated  with  4  bed  volumes  of  Ly-
sis-Equilibration-Wash (LEW) buffer (50mM sodium 
dihydrogen phosphate, 300mM sodium chloride, pH 
8.0),  and  the  cleared  sample  containing  N-terminal 
His-tagged gAd-GLP-1-A fusion protein was applied 
to the column, followed by washing with 8 bed vol-
umes of LEW buffer to remove the unbound protein. 
The target protein was eluted with 5-10 bed volumes 
of  elution  buffer  (50mM  sodium  dihydrogen  phos-
phate,  300mM  sodium  chloride,  250mM  imidazole, 
8M urea, pH 8.0). At last, fractions containing pure 
target  protein  were  collected  and  analyzed  by 
SDS–PAGE.  
The  purified  N-terminal  His-tagged 
gAd-GLP-1-A fusion protein containing 8M urea was 
then refolded in urea gradient (6, 4, 2, 1 and 0 M) re-
folding buffer (20mM Tris-HCl, 1mM EDTA, 0.2mM 
oxidized glutathione, 2mM reduced glutathione, 0.6M 
L-arginine,  10%  glycerin)  at  4°C.  The  buffer  was 
changed  every  12h.  The  protein  concentration  was 
measured by BCA Protein Assay Kit. PEG20000 was 
used to concentrate the refolded protein. 
Removal of N-terminal His-tag 
The refolded protein was incubated with enter-
okinase  (1U  enterokinase  was  added  in  0.5mg  re-
folded  protein)  at  22°C  for  16h  to  produce 
gAd-GLP-1-A fusion protein. The digested products 
were analyzed by SDS-PAGE and Western blot anal-
ysis.  
Assay of glucose-lowering effect of gAd-GLP-1-A 
fusion protein 
Male  KM  mice  were  housed  at  23-25°C  in  a 
12-hour  light/dark  cycle  with  access  to  standard 
powdered mice chow and normal water. The scientific 
project,  including  animal  care  was  supervised  and 
approved by Animals Ethics Committee of the Second 
Affiliated  Hospital,  Zhejiang  University.  They  were 
allowed one week to adapt to their environment be-
fore  the  experiment.  And  then,  the  mice  were  ran-
domly  divided  into  three  groups:  normal  control 
group,  diabetic  control  group,  and  diabetic  treated 
group.  Each  group  included  8  mice.  Diabetes  was 
induced in mice by a single intraperitoneal injection of 
streptozotocin (150 mg/kg body weight, dissolved in 
sodium  citrate  buffer)  after  overnight  fasting  [10]. 
Mice in normal control group were treated with so-
dium citrate buffer. 72h after injection, the mice with 
fasting  blood  glucose  higher  than  200  mg/dl  were 
considered as successfully diabetic model mice. After 
overnight fasting, the mice in diabetic treated group 
were  treated  with  15mg/kg  body  weight  of 
gAd-GLP-1-A fusion protein by intraperitoneal injec-
tion. The mice in diabetic control group and normal 
control group were treated with the same volume of 
normal saline. Blood glucose was respectively meas-
ured at 30min, 1h, 1.5h, 2h, 2.5h and 3h after injection. 
Statistical analysis 
Data were expressed as means ± standard devi-
ations. Data were analyzed using one-way analysis of 
variance and secondary analysis for significance with 
the Turkey-Kramer post test. All analyses were per-
formed using SPSS version 11.0 (SPSS Inc., USA). P 
<0.05 was considered statistically significant. 
Results 
Expression of N-terminal His-tagged 
gAd-GLP-1-A fusion protein and Western blot 
analysis 
The Escherichia coli host strain BL21 (DE3) cells 
transformed  with  the  expression  vector 
PET28a-gAd-GLP-1-A  produced  a  recombinant  fu-
sion protein of about 25KD after IPTG induction. The 
protein consists of four domains: 6×His-tag, entero-
kinase  cleavage  site  (DDDDK),  GLP-1-A  (31  amino 
acids),  linker  (glycine-rich  short  peptide,  15  amino 
acids), and gAd (137 amino acids) (Fig. 1A). The fu-Int. J. Med. Sci. 2011, 8 
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sion  protein  was  absent  in  non-induced  condition. 
SDS-PAGE analysis showed that most of the fusion 
protein was in inclusion body (Fig. 2A). Western blot 
using  mouse  anti-His-tag  monoclonal  antibody  also 
proved that majority of fusion protein was present in 
inclusion body (Fig. 2B). 
 
 
Figure 1 Maps of N-terminal His-tagged gAd-GLP-1-A fusion protein and gAd-GLP-1-A fusion protein. (A) N-terminal 
His-tagged gAd-GLP-1-A fusion protein; (B) gAd-GLP-1-A fusion protein. 
 
Figure 2 Expression of N-terminal His-tagged gAd-GLP-1-A fusion protein. Before IPTG induction, part of Escherichia coli 
BL21 (DE3) transformed with recombinant vector were collected and lysed. The lysate was analyzed by 12% SDS-PAGE. 
After IPTG induction, the Escherichia coli BL21 (DE3) transformed with recombinant vector were sonicated and centrifuged 
to separate the supernatant and inclusion body. Part of the production was applied to 12% SDS–PAGE analysis and 
Western blot analysis. (A) SDS-PAGE analysis: Most of the fusion protein was found in inclusion body. The expected 
molecular weight of the fusion protein is about 25KD. M: protein molecular weight marker; Lane 1: inclusion body; Lane 2: 
bacterial cell lysate before IPTG induction; Lane 3: supernatant. (B) Western blot analysis: Mouse anti-His-tag monoclonal 
antibody was used for this analysis. The fusion protein was observed in both inclusion body and supernatant. But most of 
them were in inclusion body. Lane 1: inclusion body; Lane 2: supernatant. Int. J. Med. Sci. 2011, 8 
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Purification and refolding of N-terminal 
His-tagged gAd-GLP-1-A fusion protein 
The fusion protein was purified by High-Affinity 
Ni-IDA Resin. After filtering, the fusion protein was 
bound  in  the  column.  The  column  was  washed  by 
LEW  buffer  to  remove  the  unbound  protein.  And 
then, elution buffer was used to elute the fusion pro-
tein.  The  results  were  analyzed  by  12%  SDS-PAGE 
gel. No fusion protein was found in LEW buffer after 
washing the column (Fig. 3). However, we detected 
the fusion protein in elution buffer (Fig. 3). The puri-
fied N-terminal His-tagged fusion protein was then 
refolded by urea gradient refolding buffer. 
 
 
 
Figure  3  SDS-PAGE  analysis  for  the  purification  of 
N-terminal  His-tagged  gAd-GLP-1-A  fusion  protein.  M: 
protein molecular weight marker; Lane 1: purified protein in 
elution buffer; Lane 2: LEW buffer after washing column. 
 
Enterokinase cleavage of the N-terminal 
His-tagged gAd-GLP-1-A fusion protein 
To  obtain  functional  gAd-GLP-1-A  fusion  pro-
tein,  the  His-tag  must  be  removed  from  the 
N-terminal His-tagged gAd-GLP-1-A fusion protein. 
Enterokinase  can  recognize  the  sequence 
Asp-Asp-Asp-Asp-Lys (DDDDK) and cleave the pep-
tide bond after the lysine residue [9]. The enzyme can 
cleave  any  fusion  protein  that  carries  this  sequence 
[9]. The N-terminal His-tagged gAd-GLP-1-A fusion 
protein was incubated with  enterokinase to remove 
the  N-terminal  His-tag.  An  approximately  22KD 
cleavage fragment was observed after the incubation, 
which was analyzed by SDS-PAGE (Fig. 4A). Western 
blot did not detect  His-tag reactivity after enteroki-
nase cleavage, which suggested that the His-tag was 
removed  from  the  N-terminal  His-tagged 
gAd-GLP-1-A  fusion  protein  (Fig.  4B).  The  fusion 
protein  without  His-tag  was  gAd-GLP-1-A  fusion 
protein (Fig. 1B). 
 
 
Figure  4  Enterokinase  cleavage  of  the  N-terminal 
His-tagged  gAd-GLP-1-A  fusion  protein.  (A)  SDS-PAGE 
analysis:  After  enterokinase  cleavage,  we  observed  a 
cleavage  fragment  of  22KD.  The  fragment  was 
gAd-GLP-1-A fusion protein. M: protein molecular weight 
marker; Lane 1: after enterokinase cleavage; Lane 2: before 
enterokinase  cleavage.  (B)  Western  blot  analysis:  No 
His-tag reactivity was detected after cleavage. Lane 1: after 
enterokinase cleavage; Lane 2: before enterokinase cleav-
age. 
 
Glucose-lowering effect of gAd-GLP-1-A fusion 
protein 
We  investigated  the  glucose-lowering  effect  of 
gAd-GLP-1-A fusion protein in diabetic mice. Blood 
glucose was respectively measured at 30min, 1h, 
1.5h, 2h, 2.5h and 3h after injection the fusion protein. 
The  results  showed  blood  glucose  from  diabetic 
treated group was lower than that from diabetic con-
trol group. The difference was significant at 2h, 2.5h, 
and 3h after injection (P<0.05) (Table 1). 
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Table 1. Glucose-lowering effect of gAd-GLP-1-A fusion protein 
Groups (n=8)                                      Blood glucose (mg/dl) 
0h  0.5h  1h  1.5h  2h  2.5h  3h 
Normal control group  131.75±15.50  127.63±12.68  104.75±20.55  98.38±24.44  93.88±30.70  76.75±33.01  75.38±34.99 
Diabetic control group  300.63±104.69a  244.13±107.03b  222.75±104.81 b  201.38±91.64 b  209.50±87.61 a  203.75±100.30 a  180.25±111.82 b 
Diabetic treated group  294.13±89.97a  208.13±76.43  170.00±76.91  150.13±56.23  130.63±47.67c  92.63±46.12d  87.88±46.76 c 
a Compared with normal control group P<0.01; b Compared with normal control group P<0.05; c Compared with diabetic control group 
P<0.05; d Compared with diabetic control group P<0.01 
Data were given as means ± standard deviations 
 
 
Discussion 
In the present study, we developed, for the first 
time,  a  successful  protocol  for  expression  human 
gAd-GLP-1-A  fusion  protein  from  Escherichia  coli 
strain BL21 (DE3). Plasmid vector PET28a was used to 
express this fusion protein. This vector can produce 
an  N-terminal  His-tagged  protein.  His-tag  is  often 
used for protein purification [11]. The affinity of the 
His-tag for metal ions allows the fusion product to be 
quickly  separated  from  the  bulk  of  other  bacterial 
proteins  by  using  metal  chelate  affinity  chromatog-
raphy [11]. Because N-terminal His-tag may influence 
the function of protein, we designed an enterokinase 
cleavage  site  at  the  5’  terminus  of  the  gene  of  the 
gAd-GLP-1-A fusion protein, which was used to re-
move  the  His-tag  [9].  In  our  study,  most  of  the 
His-tagged fusion protein expressed from BL21 (DE3) 
was present in inclusion body. In order to recover its 
function,  the  fusion  protein  in  inclusion  body  was 
refolded in urea gradient refolding buffer. And then, 
the refolded protein was incubated with enterokinase 
to  remove  the  His-tag.  The  fusion  protein  without 
His-tag is gAd-GLP-1-A fusion protein, which exhib-
ited  significant  glucose-lowering  effect  in  diabetic 
mice. 
GLP-1 has been reported as a promising thera-
peutic agent for type 2 diabetes [3, 12]. However, the 
clinical application of native GLP-1 is hampered by its 
very short plasma half-life [5, 6, 13]. This is due to its 
rapid inactivation by dipeptidyl peptidase IV and by 
renal clearance [5, 6, 13]. Many attempts have been 
made to increase its biological half-life and its efficacy 
in  vivo  by  producing  dipeptidyl  peptidase 
IV-resistant  GLP-1 analogs  via  amino acid substitu-
tion and  hindering the renal clearance of GLP-1 by 
conjugating it to other molecules [5, 6, 13]. Circulating 
GLP-1 is inactivated after cleaving the first two amino 
acids at the N-terminus by dipeptidyl peptidase IV 
[14]. Studies reported that the replacement of alanine 
with glycine at the second site of GLP-1 could increase 
the  resistance  of  GLP-1  on  dipeptidyl  peptidase  IV 
mediated degradation [7]. This change is sufficiently 
subtle  to  retain  the  biological  activity  of  GLP-1  [7]. 
Moreover,  GLP-1  is  a  peptide  with  relatively  low 
molecular weight and small molecular size, and most 
of them may not connect with plasma albumin [15]. 
These characteristics facilitate the filtration of GLP-1 
through  kidney  [15].  Although  structural  modifica-
tion of GLP-1 may overcome degradation by dipep-
tidyl peptidase IV, this does not address the loss of 
GLP-1  by  renal  filtration  [5].  Conjugating  GLP-1  to 
other molecular may prevent renal filtration of GLP-1 
[5, 6]. Adiponectin is an adipocyte-specific secretory 
protein and plays important roles in regulating insu-
lin sensitivity and blood glucose levels [1]. The plas-
ma half-life of adiponectin is very long, about 2.5-6h 
[16].  Adiponectin  consists  of  four  domains  [2].  The 
gAd  is  its  functional  domain  [2].  No  study  has  re-
ported the half-life of gAd. However, gAd has been 
confirmed  to  have  greater  biological  activity  than 
full-length adiponectin. We selected gAd as the con-
jugating molecule of GLP-1 in our study. This design 
not only may prevent the renal filtration of GLP-1, but 
also may yield a new protein with both function of 
GLP-1 and gAd [2]. 
We designed a mutation in  the gene of GLP-1 
(7-37) in the present study. This mutation resulted in 
the substitution of glycolamine for alanine at the se-
cond site of GLP-1 (7-37) peptide. Study has reported 
that glycine-rich linker is  flexible, which allows the 
specific engineering of hinge regions into proteins to 
achieve  desired  functional  motions  [17].  We  used a 
glycine-rich short peptide including 15 amino acids to 
connect the N-terminus of globular adiponectin and 
the  C-terminus  of  GLP-1-A.  Compared  with  native 
GLP-1,  the  fusion  protein  has  a  modified  site  and 
larger molecular size, and may circumvent the rapid 
inactivation  and  renal  clearance  of  GLP-1.  Studies 
have reported N-terminus is very important for the 
biological  activity  of  GLP-1,  and  for  globular  adi-
ponectin, the C-terminus is important [2, 5, 14]. Thus, Int. J. Med. Sci. 2011, 8 
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we connected the N-terminus of globular adiponectin 
and the C- terminus of GLP-1-A through the linker, 
which could make the N-terminus of GLP-1-A and the 
C-terminus  of  gAdiponectin  be  free  and  interact 
productively with their receptor on target cells. 
In summary, we have succeeded in expressing 
the human gAd-GLP-1-A fusion protein from Esche-
richia coli  BL21  (DE3).  This  fusion  protein  exhibited 
significant  glucose-lowering  effect  in  diabetic  mice 
and may be a promising agent that can treat type 2 
daibetes  by  improving  both  insulin  resistance  and 
insulin  secretion  deficiency.  However,  we  only  ob-
served the glucose-lowering effect of the whole fusion 
protein in this study. We could not determine which 
part of the fusion protein has this effect.  The effect 
might due to either one part of fusion protein or both 
of them. In other words, we need to know whether 
each part of the fusion protein play glucose-lowering 
effect separately. We also need to know whether the 
half-life of the GLP-1-A is longer than native GLP-1 as 
well as whether fusion protein can exhibit other func-
tions of both gAd and GLP-1. Additional experiments 
should be performed to fully investigate the function 
and characteristics of the fusion protein in the future.  
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